Oklahoma City, OK12 Active Studies

Essential Tremor Clinical Trials in Oklahoma City, OK

Find 12 actively recruiting essential tremor clinical trials in Oklahoma City, OK. Connect with local research sites and explore new treatment options.

12
Active Trials
12
Sponsors
1,752
Enrolling

Recruiting Essential Tremor Studies in Oklahoma City

About Essential Tremor Clinical Trials in Oklahoma City

Essential tremor is one of the most common movement disorders, causing involuntary shaking, most often in the hands. It is different from Parkinson's disease, though the two can be confused. Treatment includes medications, focused ultrasound, and deep brain stimulation for severe cases.

There are currently 12 essential tremor clinical trials recruiting participants in Oklahoma City, OK. These studies are seeking a combined 1,752 participants. Research is being sponsored by Exelixis, University of Washington, Sun Pharmaceutical Industries Limited and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Essential Tremor Clinical Trials in Oklahoma City — FAQ

Are there essential tremor clinical trials in Oklahoma City?

Yes, there are 12 essential tremor clinical trials currently recruiting in Oklahoma City, OK. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Oklahoma City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Oklahoma City research site will contact you about next steps.

Are clinical trials in Oklahoma City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Oklahoma City studies also compensate for your time and travel.

What essential tremor treatments are being tested?

The 12 active trials in Oklahoma City are testing new therapies including novel drugs, biologics, and treatment approaches for essential tremor.

Data updated July 18, 2026 from ClinicalTrials.gov